After all the love and money, analysts speculate that J&J may swoop in with a buyout offer for Genmab
Genmab Chief Executive Jan van de Winkel doesn’t understate his affection for J&J. When the two companies tied the knot over Darzalex, the CEO described the pharma giant as “the perfect partner.”
And the affection has been reciprocated. J&J’s Paul Stoffels told Reuters’ Ben Hirshcler just now that “we love the partnership” with Genmab. Their deal included a $20 million check yesterday for their success in developing Darzalex (daratumumab) for amyloidosis — their first Phase III outside of multiple myeloma. And they’ve been making major headway in expanding the franchise for multiple myeloma, with blockbuster plans to expand their pipeline collaboration as J&J hands over royalties ranging up to 20%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.